Results 171 to 180 of about 1,121 (213)
Some of the next articles are maybe not open access.

Adverse Effects of Intravenous Immunoglobulin

Drug Safety, 1993
The range of diseases in which intravenous immunoglobulin (IVIG) is effective has expanded significantly since its initial use in primary antibody deficiency. There are at present at least 17 preparations of IVIG in use worldwide with similar profiles of adverse effects. Infusion-related effects range in severity.
S A, Misbah, H M, Chapel
openaire   +2 more sources

Intravenous Immunoglobulins for Alzheimer’s Disease

Current Alzheimer Research, 2014
Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with intracerebral accumulation of aggregated amyloid-beta (Aβ) and tau proteins, as well as neuroinflammation. Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors.
Lakshman, Puli   +2 more
openaire   +2 more sources

SAFETY OF INTRAVENOUS IMMUNOGLOBULIN

The Lancet, 1987
W L, Shaw, R R, Stewart
openaire   +2 more sources

Intravenous immunoglobulin.

Consensus statement. National Institutes of Health Consensus Development Conference, 1991
The National Institutes of Health Consensus Development Conference on Intravenous Immunoglobulin: Prevention and Treatment of Disease brought together biomedical scientists in immunology, infectious disease, and pediatrics, as well as health care providers, patients and their families, and the public to address the safe and effective uses of ...
openaire   +1 more source

Intravenous Immunoglobulin

2022
Biswajit Banik, Niraj Arora
openaire   +2 more sources

Shortage of Intravenous Immunoglobulin

Annals of Allergy, Asthma & Immunology, 1998
openaire   +2 more sources

Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections

Microorganisms, 2021
Carlo Perricone   +2 more
exaly  

Intravenous Immunoglobulin For Neonates

MCN, The American Journal of Maternal/Child Nursing, 1991
openaire   +2 more sources

Home - About - Disclaimer - Privacy